Chiral Beta-Hydroxyethylamines for Insulin-Independent Glucose Uptake
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperglycaemia, particularly in conditions like type 2 diabetes caused by insulin receptor gene mutations, are not sufficiently effective and come with significant side effects, and there is a need for novel insulin-independent mechanisms to enhance glucose uptake in skeletal muscle cells without activating classical secondary messengers like cAMP.
Innovation Solution
Development of chiral β-hydroxyethylamines that act as agonists at the β2-adrenergic receptor to increase glucose uptake in skeletal muscle, bypassing significant cAMP release and thereby reducing common side effects associated with traditional β2-adrenergic agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional β2-adrenergic agonists are used to increase glucose uptake, then glucose uptake is enhanced, but significant cAMP release occurs causing side effects
Solution Approach 1:
The patent segments the signaling pathway by using compounds that activate the β2-adrenergic receptor to stimulate glucose uptake while specifically avoiding activation of the cAMP secondary messenger system. This separates the beneficial effect (glucose uptake) from the harmful effect (cAMP-mediated side effects), allowing selective activation of desired physiological responses without triggering unwanted downstream effects.
2Reliability
If insulin-based treatments are used for hyperglycaemia, then glucose homeostasis is regulated, but severe insulin resistance in patients with receptor gene mutations renders treatment ineffective
Solution Approach 1:
Instead of using insulin to stimulate glucose uptake (the conventional approach that fails in severe insulin resistance), the patent inverts the approach by using β2-adrenergic receptor agonists to achieve the same goal of increasing glucose uptake through a completely different signaling pathway. This bypasses the defective insulin receptor pathway and activates an alternative mechanism for glucose homeostasis regulation.
3Productivity
If current hyperglycaemia treatments are used, then some glucose control is achieved, but they are not sufficiently effective for patients with severe insulin resistance
Solution Approach 1:
The patent changes the fundamental parameter of the treatment approach by shifting from insulin-based therapy to β2-adrenergic receptor-based therapy. This parameter change involves using compounds of formula (I) that activate a different receptor system with a different signaling cascade, thereby overcoming the treatment failure associated with severe insulin resistance and improving both efficacy and success rate for this patient population.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively promote glucose uptake in skeletal muscle, offering a promising treatment for hyperglycaemia and type 2 diabetes with a favorable side-effect profile by activating the β2-adrenergic receptor without significant cAMP release, potentially normalizing whole-body glucose homeostasis.
Implementation Method 1
chiral β-hydroxyethylamines that act as agonists at the β2-adrenergic receptor to increase glucose uptake in skeletal muscle
Data Source
AI summary
There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4 and n have meanings as provided in the description.